

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

**Form 10-K/A**  
(Amendment No. 1)

(Mark One)

**ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**

For the fiscal year ended **December 31, 2017**

OR

**TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**

For the transition period from \_\_\_\_\_ to \_\_\_\_\_  
Commission file number **001-37813**

**SYROS PHARMACEUTICALS, INC.**

(Exact Name of Registrant as Specified in Its Charter)

**Delaware**

(State or other jurisdiction of incorporation or organization)

**620 Memorial Drive, Suite 300**

**Cambridge, Massachusetts**

(Address of principal executive offices)

**45-3772460**

(I.R.S. Employer Identification No.)

**02139**

(Zip code)

**(617) 744-1340**

(Registrant's telephone number, including area code)

Securities registered pursuant to Section 12(b) of the Act:

**Title of Class**

**Name of Exchange on Which Registered**

**Common Stock, \$0.001 par value**

**Nasdaq Global Select Market**

Securities registered pursuant to Section 12(g) of the Act:

**None.**

Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes  No

Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes  No

Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes  No

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes  No

Indicate by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K is not contained herein, and will not be contained, to the best of the registrant's knowledge, in definitive proxy or information statements incorporated by reference in Part III of this Form 10-K or any amendment to this Form 10-K.

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of "large accelerated filer," "accelerated filer" and "smaller reporting company" in Rule 12b-2 of the Exchange Act. (Check one):

Large accelerated filer

Accelerated filer

Non-accelerated filer

Smaller reporting company

(Do not check if a smaller reporting company)

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes  No

As of June 30, 2017, the last business day of the registrant's most recently completed second fiscal quarter, the aggregate market value of the registrant's common stock held by non-affiliates was \$289,542,157, based on the last reported sale price of such stock on the Nasdaq Global Select Market as of such date.

As of August 20, 2018, the registrant had 33,654,389 shares of Common Stock, \$0.001 par value per share, outstanding.

## EXPLANATORY NOTE

Syros Pharmaceuticals, Inc. (the “Company”) is filing this Amendment No. 1 on Form 10-K/A (the “Amendment”) to its Annual Report on Form 10-K for the fiscal year ended December 31, 2017, as originally filed on March 12, 2018 (the “Original Filing”), to add a report of management’s assessment regarding internal control over financial reporting to Item 9A. In accordance with Rule 12b-15 under the Securities Exchange Act of 1934, as amended, this Amendment No. 1 amends and restates Item 9A of the Original Filing in its entirety, and Item 15 is amended to include new certifications as Exhibits 31.3 and 31.4.

This Amendment No. 1 does not update or amend any other items in the Original Filing in any way other than as described in the preceding paragraph, and the Original Filing, as amended by this Amendment No. 1, continues to speak as of the date of the Original Filing. Accordingly, this Amendment No. 1 should be read in conjunction with the Original Filing and the Company’s other filings with the Securities and Exchange Commission.

Unless we specify otherwise, all references in this Amendment to “we,” “our,” “us,” or “the Company” refer to Syros Pharmaceuticals, Inc.

## PART II

### ITEM 9A. CONTROLS AND PROCEDURES

#### Management’s Evaluation of Disclosure Controls and Procedures

We maintain “disclosure controls and procedures,” as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended, or the Exchange Act, that are designed to ensure that information required to be disclosed in the reports that we file or submit under the Exchange Act is (1) recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms and (2) accumulated and communicated to our management, including our principal executive and principal financial officer, as appropriate to allow timely decisions regarding required disclosure. Our management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives and our management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures. Our disclosure controls and procedures are designed to provide reasonable assurance of achieving their control objectives.

Our management, with the participation of our Chief Executive Officer, who serves as our principal executive and principal financial officer, has evaluated the effectiveness of our disclosure controls and procedures as of December 31, 2017. Based upon such evaluation, our Chief Executive Officer and Principal Financial Officer has concluded that our disclosure controls and procedures were effective at the reasonable assurance level as of such date.

#### Internal Control Over Financial Reporting

##### *Management’s Report on Internal Control Over Financial Reporting*

Our management is responsible for establishing and maintaining adequate internal control over our financial reporting. Internal control over financial reporting is defined in Rules 13a-15(f) and 15d-15(f) promulgated under the Exchange Act as a process designed by, or under the supervision of, our principal executive and principal financial officers and effected by our board of directors, management and other personnel to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with U.S. GAAP. Our internal control over financial reporting includes those policies and procedures that:

- pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect our transactions and dispositions of our assets;
- provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with U.S. GAAP, and that our receipts and expenditures are being made only in accordance with authorizations of our management and directors; and
- provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of our assets that could have a material effect on our financial statements.

Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

Our management assessed the effectiveness of our internal control over financial reporting as of December 31, 2017. In making this assessment, management used the criteria set forth by the Committee of Sponsoring Organizations of the Treadway Commission (COSO) in its 2013 Internal Control — Integrated Framework. Based on our assessment, our management has concluded that, as of December 31, 2017, our internal control over financial reporting is effective based on those criteria.

This Annual Report on Form 10-K does not include an attestation report of our independent registered public accounting firm regarding internal control over financial reporting due to an exemption established by the Jumpstart Our Business Startups Act of 2012 for “emerging growth companies.”

### **Changes in Internal Control Over Financial Reporting**

During the year ended December 31, 2017, we implemented an accounting system for purposes of tracking and accounting for stock-based awards, as well as an enterprise resource system for the purposes of maintaining our general ledger and reporting. There were no other changes in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) during the year ended December 31, 2017 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

## PART IV

### ITEM 15. EXHIBITS AND FINANCIAL STATEMENT SCHEDULES

#### (b) Exhibits

| Exhibit No.   | Description   | Incorporation by Reference |                 |                | Filed with this 10-K |
|---|---|----------------------------|-----------------|----------------|----------------------|
|   |   | Form                       | SEC Filing Date | Exhibit Number |                      |
| <b>Organizational Documents and Documents Related to Common Stock</b> |   |                            |                 |                |                      |
| 3.1   | <a href="#">Restated Certificate of Incorporation of the Registrant</a>   | 8-K                        | 7/6/16          | 3.1            |                      |
| 3.2   | <a href="#">Amended and Restated Bylaws of the Registrant</a>   | 8-K                        | 7/6/16          | 3.2            |                      |
| 4.1   | <a href="#">Form of common stock certificate</a>  | S-1^                       | 6/3/16          | 4.1            |                      |
| 4.2   | <a href="#">Second Amended and Restated Investors' Rights Agreement dated October 9, 2014, as amended, among the Registrant and the other parties thereto</a>   | S-1^                       | 6/3/16          | 4.2            |                      |
| 4.3   | <a href="#">Sales Agreement dated July 20, 2017 by and between the Registrant and Cowen and Company LLC</a>   | S-3^^                      | 7/20/17         | 1.2            |                      |
| 4.4   | <a href="#">Stock Purchase Agreement dated January 8, 2018 by and between the Registrant and Incyte Corporation, as amended</a>   | 10-K                       | 3/12/18         | 4.4            |                      |
| 4.5   | <a href="#">Underwriting Agreement dated January 30, 2018 by and among the Registrant, J.P. Morgan Securities LLC, Cowen and Company, LLC and Piper Jaffray and Co., as representatives of the several underwriters named therein</a> | 8-K                        | 1/31/18         | 1.1            |                      |
| 4.6   | <a href="#">Securities Purchase Agreement dated April 20, 2017 by and among the Registrant and the persons party thereto</a>  | 8-K                        | 4/21/17         | 10.1           |                      |
| 4.7   | <a href="#">Registration Rights Agreement, dated April 20, 2017, by and among the Registrant and the persons party thereto</a>  | 8-K                        | 4/21/17         | 10.2           |                      |
| <b>Equity Plan Documents</b>  |   |                            |                 |                |                      |
| 10.1*   | <a href="#">2012 Equity Incentive Plan, as amended</a>  | S-1^                       | 6/3/16          | 10.1           |                      |
| 10.2*   | <a href="#">Form of Incentive Stock Option Agreement under 2012 Equity Incentive Plan</a>   | S-1^                       | 6/3/16          | 10.2           |                      |
| 10.3*   | <a href="#">Form of Nonstatutory Stock Option Agreement under 2012 Equity Incentive Plan</a>  | S-1^                       | 6/3/16          | 10.3           |                      |
| 10.4*   | <a href="#">Form of Restricted Stock Agreement under 2012 Equity Incentive Plan</a>   | S-1^                       | 6/3/16          | 10.4           |                      |
| 10.5*   | <a href="#">2016 Stock Incentive Plan</a>   | S-1^                       | 6/3/16          | 10.5           |                      |
| 10.6*   | <a href="#">Form of Incentive Stock Option Agreement under 2016 Stock Incentive Plan</a>  | S-1^                       | 6/3/16          | 10.6           |                      |
| 10.7*   | <a href="#">Form of Nonstatutory Stock Option Agreement under 2016 Stock Incentive Plan</a>   | S-1^                       | 6/3/16          | 10.7           |                      |
| 10.8*   | <a href="#">2016 Employee Stock Purchase Plan</a>   | S-1^                       | 6/3/16          | 10.8           |                      |
| <b>Agreements with Directors and Executive Officers</b>               |   |                            |                 |                |                      |
| 10.9*   | <a href="#">Offer Letter, dated November 13, 2012 and effective as of July 2, 2012 by and between the Registrant and Nancy Simonian, M.D., as amended</a>   | S-1^                       | 6/3/16          | 10.9           |                      |
| 10.10*  | <a href="#">Offer Letter dated August 25, 2015 by and between the Registrant and Kyle D. Kovalanka, as amended</a>  | S-1^                       | 6/3/16          | 10.10          |                      |

|        |   |      |         |       |
|--------|---|------|---------|-------|
| 10.11* | <a href="#">Offer Letter dated December 2, 2015 by and between the Registrant and David A. Roth, M.D., as amended</a>           | S-1^ | 6/3/16  | 10.11 |
| 10.12* | <a href="#">Offer Letter dated September 9, 2016 by and between the Registrant and Gerald E. Quirk, Esq.</a>                    | 10-K | 3/20/17 | 10.12 |
| 10.13* | <a href="#">Offer Letter dated November 6, 2017 by and between the Registrant and Jeremy Springhorn, Ph.D.</a>                  | 10-K | 3/12/18 | 10.13 |
| 10.14* | <a href="#">Consulting Agreement dated August 8, 2012 by and between the Registrant and Richard A. Young, Ph.D., as amended</a> | 10-K | 3/20/17 | 10.13 |

|        |   |      |        |       |
|--------|---|------|--------|-------|
| 10.15* | <a href="#">Form of Director and Officer Indemnification Agreement by and between the Registrant and each of the directors and executive officers of the Registrant</a> | S-1^ | 6/3/16 | 10.12 |
|--------|---|------|--------|-------|

**License and Collaboration Agreements**

|        |   |      |         |       |
|--------|---|------|---------|-------|
| 10.16+ | <a href="#">Exclusive License Agreement dated February 22, 2013 by and between the Registrant and the Dana-Farber Cancer Institute, Inc.</a>  | S-1^ | 6/3/16  | 10.13 |
| 10.17+ | <a href="#">Exclusive License Agreement dated April 1, 2013 by and among the Registrant, the Whitehead Institute for Biomedical Research and the Dana-Farber Cancer Institute, Inc.</a> | S-1^ | 6/3/16  | 10.14 |
| 10.18+ | <a href="#">Exclusive License Agreement dated April 4, 2013 by and between the Registrant and the Whitehead Institute for Biomedical Research</a>                                       | S-1^ | 6/3/16  | 10.15 |
| 10.19+ | <a href="#">Amended and Restated Cancer License Agreement dated April 28, 2016 by and between the Registrant and TMRC Co., Ltd.</a>   | S-1^ | 6/3/16  | 10.16 |
| 10.20+ | <a href="#">Supply Management Agreement dated April 28, 2016 by and between the Registrant and TMRC Co., Ltd.</a>   | S-1^ | 6/3/16  | 10.18 |
| 10.21  | <a href="#">Consent and Stand-by License Agreement dated April 28, 2016 by and among the Registrant, Toko Pharmaceutical Ind. Co., Ltd. and TMRC Co., Ltd.</a>                          | S-1^ | 6/3/16  | 10.19 |
| 10.22+ | <a href="#">Target Discovery, Research Collaboration and Option Agreement dated January 8, 2018 by and between the Registrant and Incyte Corporation</a>                                | 10-K | 3/12/18 | 10.22 |

**Leases**

|       |   |      |        |       |
|-------|---|------|--------|-------|
| 10.23 | <a href="#">Lease dated March 13, 2015 by and between the Registrant and 620 Memorial Leasehold LLC</a> | S-1^ | 6/3/16 | 10.17 |
|-------|---|------|--------|-------|

**Subsidiaries, Consents and Certifications**

|       |  |      |         |      |
|-------|--|------|---------|------|
| 21.1  | <a href="#">Subsidiaries of the Registrant</a>   | 10-K | 3/12/18 | 21.1 |
| 23.1  | <a href="#">Consent of Ernst &amp; Young LLP, independent public accounting firm</a>   | 10-K | 3/12/18 | 23.1 |
| 31.1  | <a href="#">Certification of principal executive officer pursuant to Rule 13a-14(a)/15d-14(a) of the Securities Exchange Act of 1934, as amended</a>       | 10-K | 3/12/18 | 31.1 |
| 31.2  | <a href="#">Certification of principal financial officer pursuant to Rule 13a-14(a)/15d-14(a) of the Securities Exchange Act of 1934, as amended</a>       | 10-K | 3/12/18 | 31.2 |
| 31.3  | <a href="#">Certification of principal executive officer pursuant to Rule 13a-14(a)/15d-14(a) of the Securities Exchange Act of 1934, as amended</a>       |      |         | X    |
| 31.4  | <a href="#">Certification of principal financial officer pursuant to Rule 13a-14(a)/15d-14(a) of the Securities Exchange Act of 1934, as amended</a>       |      |         | X    |
| 32.1# | <a href="#">Statement of principal executive officer pursuant to 18 U.S.C. §1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</a> | 10-K | 3/12/18 | 32.1 |
| 32.2# | <a href="#">Statement of principal financial officer pursuant to 18 U.S.C. §1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</a> | 10-K | 3/12/18 | 32.2 |

**XBRL Documents**

|         |  |      |         |         |
|---------|--|------|---------|---------|
| 101.INS | XBRL Instance Document                               | 10-K | 3/12/18 | 101.INS |
| 101.SCH | XBRL Taxonomy Extension Schema Document              | 10-K | 3/12/18 | 101.SCH |
| 101.CAL | XBRL Calculation Linkbase Document                   | 10-K | 3/12/18 | 101.CAL |
| 101.DEF | XBRL Taxonomy Extension Definition Linkbase Document | 10-K | 3/12/18 | 101.DEF |
| 101.LAB | XBRL Label Linkbase Document                         | 10-K | 3/12/18 | 101.LAB |
| 101.PRE | XBRL Taxonomy Presentation Linkbase Document         | 10-K | 3/12/18 | 101.PRE |

\* Indicates management contract or compensatory plan.

+ Confidential treatment has been requested and/or granted as to certain portions, which portions have been omitted and filed separately with the U.S. Securities and Exchange Commission

^ SEC File No. 333-211818

# This certification will not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liability of that section. Such certification will not be deemed to be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except to the extent specifically incorporated by reference into such filing.

**SIGNATURES**

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

**SYROS PHARMACEUTICALS, INC.**

Date: August 24, 2018

By: /s/ Nancy Simonian, M.D.  
Nancy Simonian, M.D.  
*President and Chief Executive Officer*

## CERTIFICATIONS

I, Nancy Simonian, certify that:

1. I have reviewed this Amendment No. 1 on Form 10-K/A of Syros Pharmaceuticals, Inc.;
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
  - a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
  - b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
  - c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
  - d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
4. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
  - a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
  - b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: August 24, 2018

By: /s/ Nancy Simonian, M.D.  
Nancy Simonian, M.D.  
President and Chief Executive Officer  
(Principal Executive Officer)

---

## CERTIFICATIONS

I, Joseph J. Ferra, Jr., certify that:

1. I have reviewed this Amendment No. 1 on Form 10-K/A of Syros Pharmaceuticals, Inc.;
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
  - a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
  - b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
  - c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
  - d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
4. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
  - a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
  - b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: August 24, 2018

By: /s/ Joseph J. Ferra, Jr.  
Joseph J. Ferra, Jr.  
Chief Financial Officer  
(Principal Financial Officer)

---